Last reviewed · How we verify
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.
Details
| Lead sponsor | University of Utah |
|---|---|
| Phase | PHASE2 |
| Status | TERMINATED |
| Enrolment | 6 |
| Start date | Fri Mar 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Feb 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Anemia
- ASXL1 Gene Mutation
- EZH2 Gene Mutation
- IDH1 Gene Mutation
- IDH2 Gene Mutation
- Plasma Cell Myeloma
- Primary Myelofibrosis
- Recurrent Plasma Cell Myeloma
- Secondary Myelofibrosis
- Thrombocytopenia
Interventions
- Busulfan
- Cyclophosphamide
- Fludarabine
- Hematopoietic Cell Transplantation
- Laboratory Biomarker Analysis
Countries
United States